



Bennett Jones

February 8, 2021

FILED BY SEDAR

TO: British Columbia Securities Commission, as principal regulator
AND TO: Ontario Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan, Securities Division
Manitoba Securities Commission
Financial and Consumer Services Commission, New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities, Newfoundland and Labrador

Dear Sirs/Mesdames:

Re: MYDECINE INNOVATIONS GROUP INC. – Final Short Form Prospectus

We refer to the final short form prospectus of Mydecine Innovations Group Inc. (the "**Company**") dated February 8, 2021 (the "**Prospectus**") relating to the distribution of units of the Company.

We hereby consent, as counsel to Canaccord Genuity Corp, to the use of our firm's name on page iv of the Prospectus and under the heading "*Legal Matters and Interest of Experts*".

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are within our knowledge as a result of the services performed by us in connection with the preparation of the Prospectus.

Yours truly,

(signed) "*Bennett Jones LLP*"